Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Month, Multicenter, Open-Label Extension Study (F202) to Evaluate the Long-term Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia

NCT02015234 is registered in ClinicalTrials.gov with Tonix Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02015234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02015234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Month, Multicenter, Open-Label Extension Study (F202) to Evaluate the Long-term Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Lead sponsor
Tonix Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2013
Completion date
August 31, 2015
Enrollment
158 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

primary fibromyalgia